ChiCTR2300073859 版本V1.0 版本创建时间2023/07/24 11:21:42 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2300073859 

最近更新日期:

Date of Last Refreshed on:

2023-07-24 11:21:22 

注册时间:

Date of Registration:

2023-07-24 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

基于可穿戴设备在2型糖尿病患者医院-家庭过渡期应用研究

Public title:

Effectiveness of hospital-family transition management based on wearable devices in patients with type 2 diabetes mellitus

注册题目简写:

English Acronym:

研究课题的正式科学名称:

基于可穿戴设备在2型糖尿病患者医院-家庭过渡期应用研究

Scientific title:

Effectiveness of hospital-family transition management based on wearable devices in patients with type 2 diabetes mellitus

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

高媛 

研究负责人:

周敏 

Applicant:

Gao Yuan 

Study leader:

Zhou min 

申请注册联系人电话:

Applicant telephone:

+86 147 6372 5269

研究负责人电话:

Study leader's
telephone:

+86 139 7092 1313

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

1585231068@qq.com

研究负责人电子邮件:

Study leader's E-mail:

zhoumin20220516@163.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

江西省南昌市东湖区民德路1号

研究负责人通讯地址:

江西省南昌市东湖区民德路1号

Applicant address:

No.1, Minde Road, Donghu District, Nanchang, Jiangxi

Study leader's address:

No.1, Minde Road, Donghu District, Nanchang, Jiangxi

申请注册联系人邮政编码:

Applicant postcode:

330000

研究负责人邮政编码:

Study leader's postcode:

330000

申请人所在单位:

南昌大学第二附属医院

Applicant's institution:

The Second Affiliated Hospital of Nanchang University

研究负责人所在单位:

南昌大学第二附属医院

Affiliation of the Leader:

The Second Affiliated Hospital of Nanchang University

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

I-医研伦审[2023]第(25)号

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

南昌大学第二附属医院生物医学研究伦理委员会

Name of the ethic committee:

Ethics Committee of Biomedical Research in the Second Affiliated Hospital of Nanchang University

伦理委员会批准日期:

Date of approved by ethic committee:

2023-04-13 00:00:00

伦理委员会联系人:

徐丽

Contact Name of the ethic committee:

Xu Li

伦理委员会联系地址:

江西省南昌市东湖区民德路1号

Contact Address of the ethic committee:

No.1, Minde Road, Donghu District, Nanchang, Jiangxi

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 791 8620 9562

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

南昌大学第二附属医院

Primary sponsor:

The Second Affiliated Hospital of Nanchang University

研究实施负责(组长)单位地址:

江西省南昌市东湖区民德路1号

Primary sponsor's address:

No.1, Minde Road, Donghu District, Nanchang, Jiangxi

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

江西省

市(区县):

南昌市

Country:

China

Province:

Jiangxi province

City:

Nanchang

单位(医院):

南昌大学第二附属医院

具体地址:

江西省南昌市东湖区民德路1号

Institution
hospital:

The Second Affiliated Hospital of Nanchang University

Address:

No.1, Minde Road, Donghu District, Nanchang, Jiangxi

经费或物资来源:

江西省科学技术厅重点研发计划

Source(s) of funding:

Jiangxi Provincial Science and Technology Department Key R&D Program

研究疾病:

2型糖尿病  

Target disease:

type 2 diabetes mellitus

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

本研究旨在构建基于可穿戴设备并以PPM模型为框架的2型糖尿病医院-家庭过渡期管理方案。探讨该方案对2型糖尿病患者血糖指标(糖尿病血红蛋白水平、目标范围内时间(TIR))、自我管理行为、用药依从性的干预效果。  

Objectives of Study:

The purpose of this study is to construct a hospital-family transition management plan for type 2 diabetes based on wearable devices and within the framework of PPM model. To explore the intervention effect of this scheme on blood glucose indexes (diabetic hemoglobin level, target time (TIR)), self-management behavior and medication compliance in patients with type 2 diabetes mellitus.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

①符合《中国 T2DM 防治指南(2020年版)》诊断标准,经临床医师诊断为2型糖尿病且明确诊断时间≥6 个月;②年龄≥18岁;③意识清醒且无认知功能障碍,能够配合完成研究;④能够使用智能手机;⑤自愿参与本研究。

Inclusion criteria

①In accordance with the diagnostic criteria of Chinese guidelines for prevention and treatment of T2DM (2020 edition), type 2 diabetes was diagnosed by clinicians and the diagnosis time was more than 6 months;②age ≥ 18 years old; ③ conscious and without cognitive impairment, able to cooperate with the study; ④ able to use smart phones;?⑤volunteer to participate in this study.

排除标准:

①合并重度水肿、感染、末梢循环障碍的患者;②合并严重心血管疾病、肾脏疾病及恶性肿瘤患者;③孕妇及哺乳期妇女;④患有听力或视力障碍患者。

Exclusion criteria:

①patients with severe edema, infection and peripheral circulation disturbance;② patients with severe cardiovascular disease, kidney disease and malignant tumor;③ pregnant and lactating women, and ④hearing or vision impairment.

研究实施时间:

Study execute time:

From 2023-04-13 00:00:00 To 2024-06-30 00:00:00  

征募观察对象时间:

Recruiting time:

From 2023-07-24 00:00:00 To 2024-06-30 00:00:00

干预措施:

Interventions:

组别:

对照组

样本量:

32

Group:

control group

Sample size:

干预措施:

常规管理

干预措施代码:

Intervention:

General Management

Intervention code:

组别:

干预组

样本量:

32

Group:

Intervention group

Sample size:

干预措施:

常规管理+基于可穿戴设备的医院-家庭过渡期管理

干预措施代码:

Intervention:

General Management+Hospital-family Transition Management Based on Wearable Devices

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

江西省 

市(区县):

南昌市 

Country:

China

Province:

Jiangxi province

City:

Nanchang

单位(医院):

南昌大学第二附属医院 

单位级别:

三级甲等 

Institution
hospital:

The Second Affiliated Hospital of Nanchang University

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

糖化血红蛋白

指标类型:

主要指标

Outcome:

glycated hemoglobin A1c

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

葡萄糖目标范围内时间

指标类型:

主要指标

Outcome:

time in range ,TIR

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

低血糖发生次数

指标类型:

主要指标

Outcome:

Frequency of hypoglycemia

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

2型糖尿病自我管理行为量表

指标类型:

次要指标

Outcome:

Type 2 Diabetes self-Management behavior scale

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

Morisky服药依从性量表中文版

指标类型:

次要指标

Outcome:

Morisky Medication Adherence Scale

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

Blood

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 80 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

由本研究质量控制人员采用Excel随机数字表法,将研究对象随机分至对照组和干预组。

Randomization Procedure (please state who generates the random number sequence and by what method):

By using Excel random number table method, the quality control personnel of this study randomly divided the subjects into control group and intervention group.

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

NA

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

暂无计划共享原始数据

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

There is no shared original data plan for the time being

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

本次试验数据管理采用电子化数据管理系统。根据研究方案、研究病历构建病例记录表。

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

..

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2023-07-24 11:21:22